Studied in registered human trials with published pharmacokinetic data, but not approved. Dosing outside a trial protocol has no established safety margin.
Plasma half-life of 4 minutes, stated in a human study that contrasts it with kisspeptin-54 at 27.6 minutes. Kisspeptin-10 is rapidly degraded by serum proteases. This figure is quoted in the text of a human study rather than derived from a dedicated pharmacokinetic analysis, hence medium confidence.
Model a dosing schedule →All published human dosing is weight-based and infusion-based; a fixed mcg range would require assuming a body weight. Real figures in original units: IV boluses of 0.01-3.0 mcg/kg (maximal LH stimulation at 1 mcg/kg) and continuous infusions at 1.5-4 mcg/kg/h in healthy men. These are research protocol doses in a monitored clinical setting, not a validated therapeutic range.
No approved label, therefore no established contraindications and no characterised adverse-event rates. The human studies are small (single- to low-double-digit healthy young male volunteers, short IV exposure) and are not powered to detect uncommon or long-term harms, absence of reported adverse effects in them is not evidence of safety. Kisspeptin-10 is a potent stimulator of the hypothalamic-pituitary-gonadal axis, so endocrine disruption is a mechanistically expected risk outside a monitored setting. Effects differ between men and women. Safety in women, in pregnancy, and with repeated subcutaneous self-administration is not established.